Inventor · disambiguated record
Jonathan W. Kotula
Also filed as: KOTULA JONATHAN · KOTULA JONATHAN W
24 granted patents·21 pending applications·170 citations·filing 2014–2023
95Inventor score
Files withSYNLOGIC OPERATING CO INC29SYNLOGIC INC10NOVOME BIOTECHNOLOGIES INC3HARVARD COLLEGE2MASSACHUSETTS INST TECHNOLOGY1
Top patents by PatentIndex Score
45 records- 0196US10273489B2Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrierSYNLOGIC OPERATING CO INC·Filed 2016·Granted Apr 30, 2019·12 cites·6 claims
- 0296US9688967B2Bacteria engineered to treat diseases associated with hyperammonemiaSYNLOGIC INC·Filed 2016·Granted Jun 27, 2017·36 cites·20 claims
- 0395US9889164B2Bacteria engineered to treat a disease or disorderSYNLOGIC INC·Filed 2016·Granted Feb 13, 2018·27 cites·20 claims
- 0495US9487764B2Bacteria engineered to treat diseases associated with hyperammonemiaSYNLOGIC INC·Filed 2015·Granted Nov 8, 2016·31 cites·18 claims
- 0594US11291693B2Bacteria engineered to treat metabolic diseasesSYNLOGIC OPERATING CO INC·Filed 2016·Granted Apr 5, 2022·9 cites·19 claims
- 0694US10933102B2Bacteria engineered to treat a disease or disorderSYNLOGIC OPERATING CO INC·Filed 2017·Granted Mar 2, 2021·7 cites·22 claims
- 0794US10610546B2Bacteria engineered to reduce hyperphenylalaninemiaSYNLOGIC OPERATING CO INC·Filed 2016·Granted Apr 7, 2020·7 cites·8 claims
- 0893US11471494B2Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cellsSYNLOGIC OPERATING CO INC·Filed 2018·Granted Oct 18, 2022·7 cites·10 claims
- 0992US11060073B2Bacteria engineered to treat diseases associated with hyperammonemiaSYNLOGIC OPERATING CO INC·Filed 2017·Granted Jul 13, 2021·5 cites·38 claims
- 1091US11723932B2Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cellsSYNLOGIC OPERATING CO INC·Filed 2017·Granted Aug 15, 2023·5 cites·7 claims
- 1190US11618894B2Bacteria engineered to reduce hyperphenylalaninemiaSYNLOGIC OPERATING CO INC·Filed 2016·Granted Apr 4, 2023·5 cites·33 claims
- 1289US10195234B2Bacteria engineered to reduce hyperphenylalaninemiaSYNLOGIC OPERATING CO INC·Filed 2016·Granted Feb 5, 2019·6 cites·15 claims
- 1387US9943555B2Bacteria engineered to reduce hyperphenylalaninemiaSYNLOGIC INC·Filed 2016·Granted Apr 17, 2018·5 cites·14 claims
- 1485US11879123B2Bacteria for the treatment of disordersSYNLOGIC OPERATING CO INC·Filed 2018·Granted Jan 23, 2024·4 cites·24 claims
- 1585US10047405B2Engineered genetic enteric sensor bacteria and uses thereofHARVARD COLLEGE·Filed 2014·Granted Aug 14, 2018·4 cites·20 claims
- 1674US2024382536A1Bacteria engineered to treat a disease or disorderSYNLOGIC OPERATING CO INC·Filed 2023·Application pending·0 cites
- 1773US11845964B2Bacteria engineered to treat diseases associated with hyperammonemiaSYNLOGIC OPERATING CO INC·Filed 2020·Granted Dec 19, 2023·0 cites·20 claims
- 1873US2024076645A1Bacteria engineered to reduce hyperphenylalaninemiaSYNLOGIC OPERATING CO INC·Filed 2022·Application pending·0 cites
- 1972US12409195B2Bacteria engineered to reduce hyperphenylalaninemiaSYNLOGIC OPERATING CO INC·Filed 2020·Granted Sep 9, 2025·0 cites·9 claims
- 2072US2021095297A1Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal BarrierSYNLOGIC OPERATING CO INC·Filed 2020·Application pending·0 cites
- 2171US11896627B2Bacteria engineered to treat metabolic diseasesSYNLOGIC OPERATING CO INC·Filed 2022·Granted Feb 13, 2024·0 cites·22 claims
- 2269US2023226122A1Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cellsSYNLOGIC OPERATING CO INC·Filed 2022·Application pending·0 cites
- 2367US2018273956A1Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal BarrierSYNLOGIC INC·Filed 2018·Application pending·0 cites
- 2467US2024110192A1Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrierSYNLOGIC OPERATING CO INC·Filed 2023·Application pending·0 cites
- 2566US11883439B2Bacteria engineered to treat a disease or disorderSYNLOGIC OPERATING CO INC·Filed 2020·Granted Jan 30, 2024·0 cites·17 claims
- 2665US11384359B2Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrierSYNLOGIC OPERATING CO INC·Filed 2016·Granted Jul 12, 2022·0 cites·18 claims
- 2764US2024180974A1Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cellsSYNLOGIC OPERATING CO INC·Filed 2023·Application pending·0 cites
- 2862US2022233609A1Bacteria engineered to treat disorders in which oxalate is detrimentalSYNLOGIC OPERATING CO INC·Filed 2022·Application pending·0 cites
- 2961US2016206666A1Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrierSYNLOGIC INC·Filed 2015·Application pending·0 cites
- 3059US10907221B2Engineered genetic enteric sensor bacteria and uses thereofHARVARD COLLEGE·Filed 2018·Granted Feb 2, 2021·0 cites·10 claims
- 3156US2022168362A1Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acidSYNLOGIC OPERATING CO INC·Filed 2021·Application pending·0 cites
- 3256US2023043588A1Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrierSYNLOGIC OPERATING CO INC·Filed 2022·Application pending·0 cites
- 3354US11685925B2Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrierSYNLOGIC OPERATING CO INC·Filed 2016·Granted Jun 27, 2023·0 cites·17 claims
- 3454US2022290120A1Plasmids for gene editingNOVOME BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 3553US2021130806A1Engineered bacteria expressing racemase for treating diseases associated with hyperammonemiaSYNLOGIC OPERATING CO INC·Filed 2018·Application pending·0 cites
- 3653US2022362308A1Oral administration of genetically engineered bacteriaNOVOME BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 3751US11273184B2Bacteria engineered to treat disorders in which oxalate is detrimentalSYNLOGIC OPERATING CO INC·Filed 2016·Granted Mar 15, 2022·0 cites·20 claims
- 3849US2021093679A1Engineered gut microbes and uses thereofNOVOME BIOTECHNOLOGIES INC·Filed 2019·Application pending·0 cites
- 3946US11439673B2Bacteria engineered to treat liver diseaseSYNLOGIC OPERATING CO INC·Filed 2019·Granted Sep 13, 2022·0 cites·22 claims
- 4043US2021161976A1Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrierSYNLOGIC OPERATING CO INC·Filed 2017·Application pending·0 cites
- 4141US2017216370A1Bacteria engineered to treat disorders involving propionate catabolismSYNLOGIC INC·Filed 2017·Application pending·0 cites
- 4239US2019010506A1Bacteria engineered to treat metabolic diseasesSYNLOGIC INC·Filed 2016·Application pending·0 cites
- 4338US2019282628A1Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereofSYNLOGIC INC·Filed 2017·Application pending·0 cites
- 4438US2017232043A1Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acidSYNLOGIC INC·Filed 2016·Application pending·0 cites
- 4537US2017360850A1Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel diseaseMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan W. Kotula files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →